SUMMUS WORKS SMMW Aktienrückkaufprogramm Verfielfachung möglich... - 500 Beiträge pro Seite (Seite 2)

[gino]

Summus Works, Inc. Announces Business Operations to Target Diabetes Care Marketplace
Thursday August 16, 8:05 am ET


SUN VALLEY, Calif., Aug. 16, 2007 (PRIME NEWSWIRE) -- Summus Works, Inc. (Other OTC:SMMW.PK - News), due to its recent acquisition of BioPharmetics assets and business operations, announced today the company's plan of operations.
ADVERTISEMENT





The company released the following statement: ``As BioPharmetics, Inc. has increasingly worked on offering solutions to the healthcare arena, it is important to continue on this path for the benefit of the company and its shareholders. We intend to focus considerable interest in offering solutions for diabetic care. A recent study by the National Changing Diabetes Program, states that 12% of total federal healthcare was spent on Diabetes. That translates into a $645 billion marketplace here in the U.S. alone,'' stated Mr. Dan Burgess, CEO of Summus. ``The solutions the company offers are cutting-edge, appeal to managed care companies, and give the physician or healthcare coordinator, information to deliver the highest quality of patient care possible in today's healthcare environment.''

About Summus Works, Inc.

Summus Works recently closed an acquisition for the assets and business operations of BioPharmetics, Inc. Through this acquisition, the company will have the ability to market and sell a myriad of healthcare, anti-aging, and cosmeceutical products to healthcare companies, retail and wholesale companies, as well targeting certain sectors of healthcare, biotechnology, and cosmetics.

The Summus Works, Inc. logo is available at http://www.primenewswire.com/newsroom/prs/?pkgid=4093

For more information visit http://www.biopharmetics.com.

This release includes forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties including, but not limited to, the impact of competitive products, the ability to meet customer demand, the ability to manage growth, acquisitions of technology, equipment, or human resources, the effect of economic and business conditions, and the ability to attract and retain skilled personnel. The Company is not obligated to revise or update any forward-looking statements in order to reflect events or circumstances that may arise after the date of this release.



Contact:
Summus Works, Inc.
Dan Burgess
[phone]
[e-mail]

[rostha]

SUMMUS WORKS INC (U-SMMW) - News Release
Summus Works, Inc. Announces Paul Lisenby and Ben Friedman Appointed to Board of Directors

2007-08-22 13:48 ET - News Release


SUN VALLEY, Calif., Aug. 22, 2007 (PRIME NEWSWIRE) -- Summus Works, Inc. (Pink Sheets:SMMW) announced that due to its recent acquisition of BioPharmetics assets and business operations, Paul D. Lisenby and Ben Friedman of BioPharmetics have been appointed to Summus' Board of Directors.

About Summus Works, Inc.

Summus Works recently closed an acquisition for the assets and business operations of BioPharmetics, Inc. Through this acquisition the company will have the ability to market and sell a myriad of healthcare, anti-aging, and cosmeceutical products to healthcare companies, retail and wholesale companies, as well targeting certain sectors of healthcare, biotechnology, and cosmetics.

For more information visit http://www.biopharmetics.com.

The Summus Works, Inc. logo is available at http://www.primenewswire.com/newsroom/prs/?pkgid=4093



Rostha

[gino]

Antwort auf Beitrag Nr.: 31.262.140 von rostha am 22.08.07 22:40:11

BioPharmetics (BPMT) Announces Dividend Payout to Shareholders for Recent Asset Sale to Summus Works, Inc.


Company Looks to Target New Acquisition to Grow Shareholder Value

SUN VALLEY, CA, Aug 23, 2007 (MARKET WIRE via COMTEX) -- BioPharmetics, Inc. (PINKSHEETS: BPMT) announced today that on or about September 13, 2007, the Company will announce the record date and structured dividend payout of shares of Summus Works, Inc. to BioPharmetics, Inc. shareholders resultant of the recent sale of assets to BioPharmetics, Inc. Management stated that while the exact details of the dividend are currently being structured, it will be paid pro rata to BioPharmetics shareholders.
In other news, the company is actively targeting new acquisitions for the company and expects to announce pertinent material developments to that end before Labor Day weekend. Ideal acquisition targets have been identified and due diligence is underway, management concluded.

Safe Harbor

This press release contains or may contain forward-looking statements such as statements regarding the Company's growth and profitability, growth strategy, liquidity and access to public markets, operating expense reduction, and trends in the industry in which the Company operates. The forward-looking statements contained in this press release are also subject to other risks and uncertainties, including those more fully described in the Company's filings with the Securities and Exchange Commission. The Company assumes no obligation to update these forward-looking statements to reflect actual results, changes in risks, uncertainties or assumptions underlying or affecting such statements, or for prospective events that may have a retroactive effect.



Contact:
FutureTechIR for BioPharmetics
Investor Relations
[phone]



SOURCE: BioPharmetics, Inc.




Copyright 2007 Market Wire, All rights reserved.

-0-

SUBJECT CODE: Medical and Healthcare:Medical Devices
Retail:Cosmetics and Accessories
Pharmaceuticals and Biotech:Biotech

[gino]

Antwort auf Beitrag Nr.: 31.268.723 von gino am 23.08.07 14:31:16

Press Release Source: Summus Works, Inc.


Summus Works, Inc. Announces Paul Lisenby and Ben Friedman Appointed Officers
Tuesday September 4, 8:30 am ET


SUN VALLEY, Calif., Sept. 4, 2007 (PRIME NEWSWIRE) -- Summus Works, Inc. (Other OTC:SMMW.PK - News) announced the company has appointed Mr. Paul D. Lisenby as Chairman and CEO, and Mr. Ben Friedman President of the Company. Additionally, Dan Burgess and Ian Lamphere have resigned from the Board of Directors of the Company effective immediately.
About Summus Works, Inc.

Summus Works recently closed an acquisition for the assets and business operations of BioPharmetics, Inc. The company distributes healthcare, anti-aging, and cosmiceutical products to healthcare companies, retail and wholesale companies, as well targeting certain sectors of healthcare, biotechnology, and cosmetics.

For more information visit http://www.biopharmetics.com.

The Summus Works, Inc. logo is available at http://www.primenewswire.com/newsroom/prs/?pkgid=4093

This release includes forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties including, but not limited to, the impact of competitive products, the ability to meet customer demand, the ability to manage growth, acquisitions of technology, equipment, or human resources, the effect of economic and business conditions, and the ability to attract and retain skilled personnel. The Company is not obligated to revise or update any forward-looking statements in order to reflect events or circumstances that may arise after the date of this release.



Contact:
FutureTechIR
Investor Relations
[phone]
[phone]


--------------------------------------------------------------------------------
Source: Summus Works, Inc.

[rostha]

Summus Announces Corporate Restructure


Company to Change Name, Symbol, and Issue a Reverse Split

SUN VALLEY, Calif., Sep 17, 2007 (PrimeNewswire via COMTEX) -- Summus Works, Inc. (Pink Sheets:SMMW) announced the Company has announced a corporate restructure to include a name change, symbol change, and a reverse split of the Company stock, Common and Preferred. The Company issued the following statement:
"As we move the Company forward, it is imperative to have a share structure that will allow us to seek acquisitions as well as targeting an up listing to OTCBB, AMEX, or NASDAQ Small Cap Market within the next year. We will be doing a reverse split at the ratio of 8334 to 1. This adjustment in share structure is intended to decrease our outstanding Common to a more industry standard palatable to future investors, fund managers, our primary Market Makers and for up listing qualifications. Our targeted revenue projections of $60 Million for 2008 and $110 Million in 2009 will insure our current and future shareholders will continue to have value in their investment in the Company. Upon receipt of the confirmation from NASD, we will issue a statement informing the public as to our new symbol," stated Mr. Paul D. Lisenby, Chairman and CEO of Summus. "In addition, the Company will change its name to XTend Medical Corporation to better reflect our position as a major player in the healthcare sector. XTend Medical has been working on several contracts with regional and national health care providers to deliver cutting-edge technologies to insure their patients are monitored and given the best in medical care. The company's main focus is secure long term contracts that will insure the positive growth of the company now and in the future."

The Summus Works, Inc. logo is available at http://www.primenewswire.com/newsroom/prs


Rostha

[gino]

Press Release Source: Summus Works, Inc.


Summus Works, Inc. Announces Name Change, New Trading Symbol and Reverse Split
Tuesday September 25, 5:31 pm ET
Summus Works, Inc. to Change to Extend Medical, Inc. Effective on Wednesday, September 26, 2007; New Symbol: XMDC


SUN VALLEY, Calif., Sept. 25, 2007 (PRIME NEWSWIRE) -- Summus Works, Inc. (Other OTC:SMMW.PK - News) announced the Company has received final approval from NASDAQ for the name change, new trading symbol, and reverse split to become effective on Wednesday, September 26, 2007 at the open of trading. The name shall change from Summus Works, Inc. to Extend Medical Corporation. The symbol will change from ``SMMW'' to ``XMDC''. The reverse split will be based on the ratio of 8334 to 1.
ADVERTISEMENT


The Company issued the following statement:

``The process of completing the name change, new trading symbol, and reverse split has allowed the company to begin its transformation into a major player in the healthcare sector. We appreciate our current shareholder's patience regarding this matter. This corporate restructuring will allow us to execute our plans to reach our goals of $60 million in revenue for 2008 and $110 million in revenues for 2009 as well as positioning the company to seek out acquisitions in order to bring in additional revenues and value to the company. Our new structure will be 150 million authorized shares with 65 million outstanding,'' stated Mr. Paul D. Lisenby, President of Summus Works, Inc.

The Summus Works, Inc. logo is available at http://www.primenewswire.com/newsroom/prs/?pkgid=4093

Safe Harbor

This press release contains or may contain forward-looking statements such as statements regarding the Company's growth and profitability, growth strategy, liquidity and access to public markets, operating expense reduction, and trends in the industry in which the Company operates. The forward-looking statements contained in this press release are also subject to other risks and uncertainties, including those more fully described in the Company's filings with the Securities and Exchange Commission. The Company assumes no obligation to update these forward-looking statements to reflect actual results, changes in risks, uncertainties or assumptions underlying or affecting such statements, or for prospective events that may have a retroactive effect.



Contact:
FutureTechIR
Investor Relations
[phone]


--------------------------------------------------------------------------------
Source: Summus Works, Inc.

[KANTER]

SUMMUS WORKS INC (Other OTC:XMDC.PK)

Last Trade: 0.13
Trade Time: 2:14PM ET
Change: 0.71 (84.53%)
Prev Close: 0.84
Open: 0.10
Bid: N/A
Ask: N/A
1y Target Est: N/A

Day's Range: 0.10 - 0.40
52wk Range: N/A
Volume: 204,902
Avg Vol (3m): N/A
Market Cap: N/A
P/E (ttm): N/A
EPS (ttm): N/A
Div & Yield: N/A (N/A)

[KANTER]

Meine sind allerdings gesperrt!

Kann jemand die Dinger handeln???

[fab35]

Antwort auf Beitrag Nr.: 31.754.800 von KANTER am 26.09.07 20:35:55

Meine auch

fab

[BlackRifleHunter]

wann sollen wir wieder handeln können ?

[BlackRifleHunter]

SMMW heißt jetzt XTEND MEDICAL CORP , 2280918

[fab35]

Antwort auf Beitrag Nr.: 31.768.399 von BlackRifleHunter am 27.09.07 20:17:19

XMDC heute über 30% grün.
Warum kann ich den Dreck nicht endlich verkaufen
fab

[gino]

Antwort auf Beitrag Nr.: 31.780.602 von fab35 am 28.09.07 18:20:35

Press Release Source: XTend Medical Corporation


XTend Medical (XMDC) Signs Exclusive Distribution Agreement With Diabetes Detection, Inc., a Silicon Valley Company
Friday September 28, 12:12 pm ET


XTend Medical to Be First to Market Global Diabetes Technology to Millions of Physicians


SUN VALLEY, CA--(MARKET WIRE)--Sep 28, 2007 -- XTend Medical Corporation (Other OTC:XMDC.PK - News) announced the company has signed an exclusive distribution agreement with Diabetes Detection, Inc. of Palo Alto, CA, manufacturer of medical testing devices.
ADVERTISEMENT


Under the terms of the agreement, XTend will sell and distribute all medical device products developed by DDI for use in the early detection of diabetic neuropathy. Neuropathy detection is used to determine the extent to which diabetic patients lose feeling in their outer extremities. DDI's current medical testing device was developed in a pager unit wherein physicians have a mobile medical device that can check the vibration threshold of the patient, thereby determining their neuropathic loss. This can help the physician in determining the proper course of treatment to minimize any further damage to the patient's extremities and lower patient costs significantly.

"We're extremely pleased to finalize this agreement with DDI. Our company now has an additional medical device to market and sell to major healthcare companies so they can diagnose neuropathy levels in patients and assist in preventing further damage to the patient, while saving the managed care companies additional costs of patient care. With the global market of diabetic neuropathy increasing, the potential sales of this unit alone in the U.S. could well exceed $150 million over the next 3-4 years," stated Mr. Paul D. Lisenby, Chairman and CEO of XTend Medical.

For more information about DDI, please log onto www.diabetesdetectioninc.com

Safe Harbor

This press release contains or may contain forward-looking statements such as statements regarding the Company's growth and profitability, growth strategy, liquidity and access to public markets, operating expense reduction, and trends in the industry in which the Company operates. The forward-looking statements contained in this press release are also subject to other risks and uncertainties, including those more fully described in the Company's filings with the Securities and Exchange Commission. The Company assumes no obligation to update these forward-looking statements to reflect actual results, changes in risks, uncertainties or assumptions underlying or affecting such statements, or for prospective events that may have a retroactive effect.



Contact:
Company Contact:
FutureTechIR for BioPharmetics
Investor Relations
[phone]



--------------------------------------------------------------------------------
Source: XTend Medical Corporation

[KANTER]

[KANTER]

Posted by: bobky
In reply to: KingVegita2006 who wrote msg# 6709 Date:9/28/2007 2:55:58 PM
Post #of 6711

XMDC-Here are the numbers:



Based on earnings of:



2008 Estimates: $60m

-with our current share structure: (65m)

-EPS of: .92

-x’s 21 industry average: $19.32



-with our a/s: (150m)

-EPS of .40

-x’s 21 industry average: $8.40



2009 Estimates: $110m

-with our current share structure: (65m)

-EPS of: 1.69

-x’s 21 industry average: $35.49



-with our a/s: (150m)

-EPS of .73

-x’s 21 industry average: $ 15.33

[KANTER]

Würd ja lachen wenn ich hier aus der Sache tatsächlich noch im Plus rauskommen würde

[rostha]

Antwort auf Beitrag Nr.: 31.783.301 von KANTER am 28.09.07 22:13:42

Sieht aber so aus, also,wenn ich die Vorgeschichte von unserem neuen CEO so lese, hat der Mann Pouwer und eine Erfolgsgeschichte.
Ich werde so schnell nicht verkaufen, ich vermute, wenn die Aktien in unseren Depots umgewechselt sind, geht es erst richtig los.

Bei den Pinkies muss man mit allem rechnen


schönes Wochenende


Rostha

[KANTER]

Antwort auf Beitrag Nr.: 31.783.452 von rostha am 28.09.07 22:31:36

[fab35]

Antwort auf Beitrag Nr.: 31.783.452 von rostha am 28.09.07 22:31:36

....aber bei mir sind sie gesperrt bis 2049
fab

[KANTER]

Antwort auf Beitrag Nr.: 31.785.362 von fab35 am 29.09.07 13:25:59

Ja steht bei mir auch,aber ab nächste woche sollen sie wohl umgebucht sein in die neue Bude

[fab35]

Antwort auf Beitrag Nr.: 31.785.371 von KANTER am 29.09.07 13:27:14

Hallo @all.

börsenphilo hat bei XTEND MEDICAL CORPORATION nen Thread aufgemacht.
Ich denke wir sollten SMMW jetzt begraben.
Auf ein Neues.
Gruß
fab

[KANTER]

Antwort auf Beitrag Nr.: 31.793.864 von fab35 am 30.09.07 16:44:43

Schick mal n Link dazu bitte!!